Hasil Pencarian - Jeremy Aboagye

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

    Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies oleh Pedro M. Folegatti, Amy Flaxman, Daniel Jenkin, Rebecca Makinson, Lucy Kingham-Page, Duncan Bellamy, Fernando Ramos Lopez, Jonathan Sheridan, Ian Poulton, Jeremy Aboagye, Nguyen Tran, Celia Mitton, Rachel Roberts, Alison M. Lawrie, Adrian V. S. Hill, Katie J. Ewer, Sarah Gilbert

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya [version 1; peer review: 2 approved]

    Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in... oleh Omar Ngoto, Mainga Hamaluba, Emmaloise Gathuri, Sam Provstgaard-Morys, Janet Musembi, Jeremy Aboagye, Lisa Stockdale, Racheal Roberts, Daniel Woods, Francis Ndungu, Kelvias Keter, Adrian V.S. Hill, Katie J. Ewer, Alison Lawrie, Samuel Sang, Philip Bejon, Irene Njau, Benedict Orindi, Melissa Kapulu, Edward Otieno, Mehreen S. Datoo, Duncan Bellamy, Charles Muiruri, Domtila Kimani

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

    Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial oleh Meera Madhavan, Adam J. Ritchie, Jeremy Aboagye, Daniel Jenkin, Samuel Provstgaad-Morys, Iona Tarbet, Danielle Woods, Sophie Davies, Megan Baker, Abigail Platt, Amy Flaxman, Holly Smith, Sandra Belij-Rammerstorfer, Deidre Wilkins, Elizabeth J. Kelly, Tonya Villafana, Justin A. Green, Ian Poulton, Teresa Lambe, Adrian V.S. Hill, Katie J. Ewer, Alexander D. Douglas

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial

    Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial oleh Mohammad Bosaeed, MD, Hanan H Balkhy, ProfMD, Sultan Almaziad, MD, Haya A Aljami, BSc, Hind Alhatmi, MD, Hala Alanazi, BSN, Mashael Alahmadi, BSc, Ayah Jawhary, MD, Mohammed W Alenazi, BSc, Abdulrahman Almasoud, BSc, Rawan Alanazi, PharmD, Mustapha Bittaye, PhD, Jeremy Aboagye, MSc, Nahla Albaalharith, BSN, Sarah Batawi, MD, Pedro Folegatti, MSc, Fernando Ramos Lopez, MSc, Katie Ewer, PhD, Khalid Almoaikel, PhD, Majed Aljeraisy, PharmD, Adel Alothman, MD, Sarah C Gilbert, ProfPhD, Naif Khalaf Alharbi, PhD

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: